Chemotherapy and peripheral neuropathy

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a major dose-limiting side effect of many anti-cancer agents, including taxanes, platinums, vinca alkaloids, proteasome inhibitors, immunomodulatory drugs, and antibody-drug conjugates. The resultant symptoms often persist post treatment completion and continue to impact on long-term function and quality of life for cancer survivors. At present, dose reduction remains the only strategy to prevent severe neuropathy, often leading clinicians to the difficult decision of balancing maximal treatment exposure and minimal long-lasting side effects. This review examines the clinical presentations of CIPN with each class of neurotoxic treatment, describing signs, symptoms, and long-term outcomes. We provide an update on the proposed mechanisms of nerve damage and review current data on clinical and genetic risk factors contributing to CIPN development. We also examine recent areas of research in the treatment and prevention of CIPN, with specific focus on current clinical trials and consensus recommendations for CIPN management.

Automated summary

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a dose-limiting side effect of many anti-cancer agents, impacting long-term function and quality of life for cancer survivors. Dose reduction is currently the main strategy to prevent severe neuropathy, but it poses a challenge in balancing treatment efficacy and minimizing long-lasting side effects. Ongoing research focuses on understanding the mechanisms of nerve damage and identifying risk factors for CIPN development, with the goal of improving management strategies.